Actually HGEN has been rather sparing on the PRs in comparison to most startup biotechs. Also I came in here swinging every possible bear thesis I could at this company and I can say I was absolutely wrong.
Anything under 30 on this stock is probably going to be a win. I would have never thought that even with vaccines out there people would be so hesitant to take them that the requirements for treatments would still be a pressing matter.
Plus the imaging for the initial cancer results was promising so there is another application in the pipeline.